Is China Plus One A Big Tailwind For Neuland Labs? CEO Explains The Peptide Opportunity
CNBC-TV18 · 24 Sept 2026 · 1 min
Management interview of Neuland Laboratories Ltd (NEULANDLAB).
- Saharsh Davuluri, CEO, Neuland Laboratories Ltd
Neuland Laboratories' CEO highlights that the China Plus One strategy remains a meaningful tailwind. Despite ample peptide manufacturing capacity in China, innovators are increasingly seeking supply options in India, Europe, and elsewhere. The company noted that several client projects have already been moved out of China. Furthermore, incoming requests for proposals (RFPs) over the past three months reached their highest level in several years.